TECX Tectonic Therapeutic, Inc.
8-K Current Report
Filed: February 24, 2026
Health Care
Biological Products, (No Diagnostic Substances)Tectonic Therapeutic, Inc. (TECX) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items4 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 5.02 · Departure/Election of Directors or Officers
- • Terrance McGuire resigning as Board Chair effective April 1, 2026; full Board exit at 2026 annual meeting
- • François Nader appointed Board Chair (effective April 1, 2026) and Class III director through 2027 annual meeting
Item 7.01 · Regulation FD Disclosure
- • Reg FD disclosure via Exhibits 99.1 and 99.2 — content of those exhibits is the material information for investors to review
- • Filing structured as "furnished" not "filed" — limits legal liability under Exchange Act Section 18, standard for investor presentations/press releases
Other Tectonic Therapeutic, Inc. 8-K Filings
Get deeper insights on Tectonic Therapeutic, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.